Tolterodine Tartrate: Brands, Price & Uses in Bangladesh

Tolterodine Tartrate is an antimuscarinic (anticholinergic) agent approved for the treatment of overactive bladder (OAB).

Established / FDA-approved use

• Treatment of overactive bladder in adults with symptoms of urinary urgency, frequency, and urge incontinence.

Tolterodine Tartrate is not indicated for stress urinary incontinence or for children, and it has no established role as an adjunct or combination therapy for other conditions.

Dosage by formulation (overactive bladder)

Hepatic impairment

In patients with significant hepatic impairment, the recommended dose of Tolterodine Tartrate is the lower dose (1 mg twice daily for IR, or 2 mg once daily for ER).

Renal impairment

In patients with significantly reduced renal function, the recommended dose of Tolterodine Tartrate is the lower dose (1 mg twice daily for IR, or 2 mg once daily for ER).

Concomitant strong CYP3A4 inhibitors

When Tolterodine Tartrate is co-administered with a potent CYP3A4 inhibitor, the lower dose should be used (see Drug Interactions).

Pediatric use

Safety and efficacy of Tolterodine Tartrate in children have not been established; it is not recommended for pediatric use.

The most common adverse effect of Tolterodine Tartrate, consistent with its anticholinergic mechanism, is:

• Dry mouth (very common)
• Constipation
• Blurred vision / accommodation difficulty
• Dizziness
• Headache
• Dry eyes
• Dyspepsia / abdominal discomfort
• Urinary retention (uncommon, more likely with pre-existing bladder outlet obstruction)

Less common but clinically important effects

Tolterodine Tartrate can cause a dose-related prolongation of the QT interval (see Interactions and Precautions). Confusion, memory impairment, and other cognitive effects have been reported, particularly in elderly patients, due to the drug's anticholinergic burden.